Highlights and Quick Summary
- Depreciation & Amortization Growth for the quarter ending February 28, 2023 was 9.49% (a 110.42% increase compared to previous quarter)
- Year-over-year quarterly Depreciation & Amortization Growth increased by 113.26%
- Annual Depreciation & Amortization Growth for 2022 was -19.99% (a -124.02% decrease from previous year)
- Annual Depreciation & Amortization Growth for 2021 was 83.22% (a -15.9% decrease from previous year)
- Annual Depreciation & Amortization Growth for 2020 was 98.95% (a -1203.12% decrease from previous year)
- Twelve month Depreciation & Amortization Growth ending February 28, 2023 was -21.45% (a -1.38% decrease compared to previous quarter)
- Twelve month trailing Depreciation & Amortization Growth decreased by -141.26% year-over-year
Trailing Depreciation & Amortization Growth for the last four month:
| 28 Feb '23 | 30 Nov '22 | 31 Aug '22 | 31 May '22 |
|---|---|---|---|
| -21.45% | -21.75% | -19.99% | 51.99% |
Visit stockrow.com/OGI
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Depreciation & Amortization Growth of Organigram Holdings Inc.
Most recent Depreciation & Amortization Growthof OGI including historical data for past 10 years.Interactive Chart of Depreciation & Amortization Growth of Organigram Holdings Inc.
Organigram Holdings Inc. Depreciation & Amortization Growth for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | 9.49% | – | – | – | – |
| 2022 | 4.51% | -54.73% | 4.45% | 11.12% | -19.99% |
| 2021 | 20.69% | 171.77% | 41.35% | 28.41% | 83.22% |
| 2020 | 57.51% | 73.96% | 99.15% | 147.45% | 98.95% |
| 2019 | 96.68% | -66.5% | -49.79% | -59.59% | -8.97% |
| 2018 | – | – | -49.16% | 198.47% | 502.09% |
| 2017 | – | – | – | – | 104.3% |
| 2016 | – | – | – | – | -51.05% |
Business Profile of Organigram Holdings Inc.
Sector: Healthcare
Industry: Drug Manufacturers Specialty & Generic